2023
Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab
Tripathi N, Meza L, Sayegh N, Govindarajan A, Byron S, Zhang J, Chigarira B, Jo Y, Zengin Z, Li H, Gebrael G, Desai A, Agarwal N, Swami U, Maughan B, Pal S. Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab. Kidney Cancer 2023, 7: 137-145. DOI: 10.3233/kca-230011.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClear cell metastatic renal cell carcinomaClinical benefit groupRenal cell carcinomaClinical benefitNivolumab therapyCell carcinomaPoor-risk metastatic renal cell carcinomaMetastatic clear cell renal cell carcinomaBenefit groupClear cell renal cell carcinomaFirst-line ipilimumabIMDC risk scoresFirst-line treatmentCell renal cell carcinomaAlteration frequencyChi-square testMRCC patientsStable diseaseComplete responsePartial responseSystemic therapyLine treatmentInflammatory pathwaysTumor-specific gene expression
2022
Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
Ali S, Leong S, Meza L, Dizman N, Zengin Z, Kim T, Pak Y, Onyshchenko M, Pal S, Chehrazi-Raffle A. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo). Journal Of Clinical Oncology 2022, 40: 4554-4554. DOI: 10.1200/jco.2022.40.16_suppl.4554.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaIpi/nivoProgression-free survivalTertiary care centerSafety-net healthcare systemCare centerHispanic/LatinxMultivariate Cox proportional hazards regressionShorter progression-free survivalCox proportional hazards regressionSafety-net hospital systemHope Comprehensive Cancer CenterFirst-line ipilimumabFirst-line therapyImmune checkpoint inhibitorsLos Angeles County DepartmentClear cell histologyNumber of comorbiditiesKaplan-Meier methodProportional hazards regressionComprehensive cancer centerHealthcare systemRenal cell carcinomaMultiple social determinantsReal-world analysis